UPC: 023542607438
# WA0117

Kyo-Dophilus One Per Day (formerly Acidophilus Go!) is a
high potency supplement containing 3 billion live cells of
the friendly bacteria: Lactobacillus acidophilus,
Bifidobacterium bifidum, and Bifidobacterium longum One
Per Day One Month Supply (30 capsules) Strains carefully
selected and adapted to grow and work in the human
digestive tract. No refrigeration required. Guaranteed
stability at room temperature. Friendly bacteria may
nutritionally assist in the body's normal response to
yeast.1 Because friendly bacteria can be destroyed by
improper diet, stress, traveling, antibiotics, various
medications, and the aging process, this supplement can
assure a generous amount of beneficial bacteria for a
healthy intestinal tract. These bacteria may help suppress
harmful bacteria and the substances they produce along the
entire intestinal tract.2-5 SUGGESTED USE: Take one
capsule for adults (1/2 capsule for children under four) with
a meal daily. For infants, sprinkle 1/2 capsule in food or
juice. Supplement Facts Serving Size 1 capsule Product
Code: 607-43: 30 capsules Amount per serving %Daily Value
L. acidophilus, B. bifidum, and B. longum viable at the time of
consumption prior to the expiration date 3.0 billion live cells
** †Prior to the expiration date ** Daily Value not
established OTHER INGREDIENTS: Gelatin, Vegetable Starch
Complex (potato) Free of: preservatives, sugar, sodium, milk,
yeast, artificial colors and flavors. Why Human
Strains? It is important to be aware that the human
intestinal tract may be more sensitive to strains introduced to
it than those introduced to the intestinal tracts of animals.
What this means is that bacterial strains that are effective in
one species of animal are not necessarily effective in another
species. This is because the digestive tract varies from species
to species and bacteria have to have certain characteristics in
order to survive in the intestinal tract in which they are
dwelling. Specifically, bacterial strains indigenous to humans
are more likely to survive in the intestinal tracts of humans
than are non-human strains since they are specifically adapted
to grow in the intestinal tracts of humans.1,2 They must be able
to withstand stomach acid, in order to make it to the intestinal
tract. They must be able to withstand intestinal fluids and they
must be able to adhere to the lining of the intestinal tract to
exert their greatest benefits. Bacteria derived from dairy or
other sources are less likely to remain in the intestinal tract
of humans. They may afford only temporary, if any, benefits. On
the other hand, human strains show better colonization and
effectiveness. For this reason, each of our probiotic formulas
is formulated with human strains. How Were the Human
Strains Derived? The bacteria strains used in WAKUNAGA'S
PROBIOTICS were derived from single strains of bacteria donated
by Microbiology Professors from the University of Tokyo and the
Dokkyo Medical University of Japan. Each strain was obtained
from a healthy, living subject in a one time collection. The
bacteria of choice were, isolated, identified, purified and mass
produced after this single collection. Bacteria were obtained
about three decades ago and have been naturally replicating in
the laboratory every since for mass production. They undergo
numerous tests to assure the bacteria are healthy and maintain
their positive characteristics. Consuming bacteria is safer than
eating produce from the grocery store, because consistent
microscopic investigation would be impossible for produce but is
commonplace where bacteria products are concerned. Why
Take A Probiotic? By providing large numbers of these
friendly bacteria to the intestinal tract they may increase the
population of these bacteria compared to other less desirable
strains. These strains may then competitively inhibit the growth
of undesirable strains and also inhibit the production of toxic
substances produced by less desirable strains.3 Further, studies
suggest that they may stimulate our immune system to suppress
the growth of pathogenic or undesired bacteria.4-6 Any
Clinical Studies for Safety or Effectiveness? A clinical
study of 180 patients from eight different medical facilities in
Japan noted significant improvement in patients with soft stools
or diarrhea from taking a probiotic product containing
Wakunaga's Lactobacillus acidophilus (L. acidophilus) and
Bifidobacterium bifidum (B. bifidum).7 Regarding constipation, a
clinical study of 39 patients showed improvement in 95% of the
subjects after taking a multistrain product including Wakunaga's
L. acidophilus and B. bifidum.4 Another clinical study using the
same product showed improvement in 58 of 64 subjects with
constipation.7 Abdominal distension improved in 63 of 66
subjects and frequency, hardness and odor improved. Clinical
studies conducted on nearly 300 subjects revealed no side
effects in subjects taking Wakunaga Probiotics.8,9 The
probiotic strains used by Wakunaga have no toxicity based on
basic toxicological and preclinical
studies. References Salminen, S. and Wright, A. V.
(1993) ed. Lactic Acid Bacteria. Marcel Dekker Inc., New York,
pp. 200-201. Golden, B.R. and Gorbach, S.L. Ch. 13.
Probiotics. The Scientific Basis (Fuller, R., ed.), Chapman &
Hall, London, 1992, pp. 367-368. Yamashita, M., Fujisaki,
M., Ohkushi, E., Kaihatsu, K. and Uchida, S. (1987) Ecological
study of effects of administration of three kinds of lactic acid
bacteria on suppression of intestinal decomposed substance.
Clinics and Microorganisms 13(b): 87. Honma, N., Ohtani, K.
and Kikuchi, H. (1987) On effects of lactic acid bacteria. Part
II. Clinical effects. New Medicines and Clinics 36(1): 75.
Honma, N. (1986) On effects of lactic acid bacteria. Part I.
Biological significance New Medicines and Clinics 35(12):
2687-2695. Honma, N. (1974) Intestinal bacteria flora of
infants and infection protection. Pediatric Clinics 27(11): 20.
In-House Clinical Study Conducted on 180 Patients from 8
Different Medical Facilities (Kobe University and associated
hospitals.) Willard, T. (1989) Occurrence of diarrhea with
the use of Kyo-Dophilus. Chiron Consultants Inc. Calgary,
Canada. Willard, T. 1989. Kyo-Dophilus use in the reduction
of Candida albicans symptoms. Chiron Consultants Inc. Calgary,

Write a Review

Helpful Customer Reviews